Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs TelePeptide

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

TelePeptide
Site position #308

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 62.3/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +48
92
44
Dose & formulationCoreAge Rx +13
88
75
Clinical oversightCoreAge Rx +6
93
87
Labs & monitoringCoreAge Rx +36
90
54
FulfillmentCoreAge Rx +18
95
77
Contract termsCoreAge Rx +47
67
20
CoreAge Rx · top barTelePeptide · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxTelePeptide
WeighScore89.5/10062.3/100
GradeB+C
Site position#1#308
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$199/mo (starting dose, annual plan, compounded oral)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$219/mo (starting dose, annual plan, compounded oral)
CoverageUS only; therapy-specific state restrictions applyCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedYes
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
TelePeptide

Site position #308 · C

Strengths

  • LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
  • All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
  • Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
  • 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
  • 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime

What to consider

  • Compounded medications are not FDA-approved; no pharmacy partner named publicly
  • Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
  • Labs not included in any plan
  • Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
  • Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard